Nabriva Therapeutics AG
Leberstrasse 20
1110 Vienna, Austria
November 7, 2016
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Nabriva Therapeutics AG
Registration Statement on Form F-3
File No. 333-214197
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nabriva Therapeutics AG (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form F-3 (File No. 333-214197), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on November 9, 2016, or as soon thereafter as practicable.
| Very truly yours, | ||
|
| ||
|
| ||
| NABRIVA THERAPEUTICS AG | ||
|
| ||
|
| ||
| By: | /s/ Colin Broom | |
|
| Name: | Colin Broom |
|
| Title: | Chief Executive Officer |
